Trade Report: The World Asset Management Inc invests in Eli Lilly and Co. (LLY) Shares

The World Asset Management Inc invests in Eli Lilly and Co. (LLY) Shares

World Asset Management Inc increased its stake in Eli Lilly and Co. (NYSE:LLY) by 0.8% during the second quarter, Holdings Channel reports. The institutional investor owned 97,091 shares of the company’s stock after buying an additional 802 shares during the period. World Asset Management Inc’s holdings in Eli Lilly and were worth $7,646,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Iowa State Bank bought a new stake in Eli Lilly and during the second quarter valued at about $104,000. Cribstone Capital Management LLC bought a new stake in Eli Lilly and during the second quarter valued at about $117,000. Physicians Financial Services Inc. raised its stake in Eli Lilly and by 11.2% in the second quarter. Physicians Financial Services Inc. now owns 1,638 shares of the company’s stock valued at $129,000 after buying an additional 165 shares in the last quarter. Signaturefd LLC raised its stake in Eli Lilly and by 16.1% in the second quarter. Signaturefd LLC now owns 1,796 shares of the company’s stock valued at $141,000 after buying an additional 249 shares in the last quarter. Finally, Orrstown Financial Services Inc. raised its stake in Eli Lilly and by 47.1% in the second quarter. Orrstown Financial Services Inc. now owns 1,874 shares of the company’s stock valued at $148,000 after buying an additional 600 shares in the last quarter. Institutional investors own 74.99% of the company’s stock.

Shares of Eli Lilly and Co. (NYSE:LLY) traded down 2.14% during midday trading on Friday, reaching $74.53. The company’s stock had a trading volume of 5,651,541 shares. The stock has a 50 day moving average of $79.52 and a 200-day moving average of $78.09. Eli Lilly and Co. has a 1-year low of $67.88 and a 1-year high of $88.16. The company has a market capitalization of $79.06 billion, a P/E ratio of 32.42 and a beta of 0.17.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, October 25th. The company reported $0.88 earnings per share for the quarter, missing the consensus estimate of $0.96 by $0.08. The business had revenue of $5.19 billion for the quarter, compared to analyst estimates of $4.23 billion. Eli Lilly and had a return on equity of 24.06% and a net margin of 11.73%. Eli Lilly and’s revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.89 EPS. On average, equities research analysts anticipate that Eli Lilly and Co. will post $3.56 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 9th. Investors of record on Tuesday, November 15th will be paid a dividend of $0.51 per share. The ex-dividend date is Thursday, November 10th. This represents a $2.04 annualized dividend and a yield of 2.74%. Eli Lilly and’s dividend payout ratio (DPR) is 88.70%.

Several analysts have issued reports on the stock. BMO Capital Markets restated a “buy” rating and issued a $94.00 price target on shares of Eli Lilly and in a research report on Wednesday, July 27th. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $88.00 price target on the stock in a research report on Thursday, October 20th. Leerink Swann restated an “outperform” rating and issued a $105.00 price target on shares of Eli Lilly and in a research report on Saturday, August 13th. Goldman Sachs Group Inc. restated a “buy” rating and issued a $95.00 price target on shares of Eli Lilly and in a research report on Wednesday. Finally, Deutsche Bank AG restated a “buy” rating on shares of Eli Lilly and in a research report on Tuesday, September 20th. Two equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. Eli Lilly and has an average rating of “Buy” and a consensus target price of $96.74.

In other Eli Lilly and news, Director Jackson P. Tai acquired 5,773 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The shares were purchased at an average price of $80.43 per share, for a total transaction of $464,322.39. Following the completion of the purchase, the director now directly owns 42,306 shares in the company, valued at $3,402,671.58. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jackson P. Tai acquired 2,560 shares of the company’s stock in a transaction that occurred on Friday, August 12th. The shares were acquired at an average price of $80.42 per share, for a total transaction of $205,875.20. Following the purchase, the director now owns 42,110 shares of the company’s stock, valued at $3,386,486.20. The disclosure for this purchase can be found here. Corporate insiders own 0.20% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Related posts

Leave a Comment